Other
18 Authors
- Tao-Cheng JH,
- Lin X,
- Gu XL,
- Liu Z,
- Sun L,
- Troncoso JC,
- Cai H,
- Li Z,
- Chen ZZ,
- Ding J,
- Shim H,
- Gallant PE,
- Xie C,
- Parisiadou L,
- Yang WJ,
- Wang L,
- Long CX,
- Rudow G
| First Author | Lin X | Year | 2009 |
| Journal | Neuron | Volume | 64 |
| Issue | 6 | Pages | 807-27 |
| PubMed ID | 20064389 | Mgi Jnum | J:156512 |
| Mgi Id | MGI:4420803 | Doi | 10.1016/j.neuron.2009.11.006 |
| Citation | Lin X, et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64(6):807-27 |
| abstractText | Mutations in alpha-synuclein and Leucine-rich repeat kinase 2 (LRRK2) are linked to autosomal dominant forms of Parkinson's disease (PD). However, little is known about any potential pathophysiological interplay between these two PD-related genes. Here we show in transgenic mice that although overexpression of LRRK2 alone did not cause neurodegeneration, the presence of excess LRRK2 greatly accelerated the progression of neuropathological abnormalities developed in PD-related A53T alpha-synuclein transgenic mice. Moreover, we found that LRRK2 promoted the abnormal aggregation and somatic accumulation of alpha-synuclein in A53T mice, which likely resulted from the impairment of microtubule dynamics, Golgi organization, and the ubiquitin-proteasome pathway. Conversely, genetic ablation of LRRK2 preserved the Golgi structure and suppressed the aggregation and somatic accumulation of alpha-synuclein, and thereby delayed the progression of neuropathology in A53T mice. These findings demonstrate that overexpression of LRRK2 enhances alpha-synuclein-mediated cytotoxicity and suggest inhibition of LRRK2 expression as a potential therapeutic option for ameliorating alpha-synuclein-induced neurodegeneration. |
